| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Plasmodium falciparum; Antimalarial agent 13 targets the malaria parasite P. falciparum. The compound inhibits the asexual blood-stage growth of the parasite in human erythrocytes. It also shows activity against HepG2 cells, indicating some degree of cytotoxicity. The quinazoline core is a common scaffold in antimalarial drug discovery, and the compound's activity is likely due to interference with essential parasite processes.
|
|---|---|
| ln Vitro |
In vitro, Antimalarial agent 13 shows potent inhibition of P. falciparum with EC₅₀ values of 124 nM and 134.0 nM. It also inhibits HepG2 cell growth with an EC₅₀ of 2.5 μM. The compound's activity against the parasite is significantly higher than its activity against the mammalian cell line, suggesting some selectivity. The compound is typically dissolved in DMSO for in vitro assays. Its effects on parasite viability are measured using standard antimalarial assays, such as the SYBR Green-based assay.
|
| ln Vivo |
In vivo studies on Antimalarial agent 13 are limited. The compound has shown potent in vitro activity against P. falciparum. However, detailed in vivo efficacy data in animal models of malaria are not extensively documented in the available literature. The compound is primarily used as a research tool for studying antimalarial activity in vitro. Further studies are needed to evaluate its in vivo efficacy and pharmacokinetic properties.
|
| Enzyme Assay |
In vitro antimalarial activity is assessed using P. falciparum 3D7 asexual blood-stage cultures in human erythrocytes. The compound is serially diluted and added to the parasite cultures. After 72 hours of incubation, parasite viability is measured using a SYBR Green-based fluorescence assay. The EC₅₀ is determined by plotting the percentage inhibition against the compound concentration. Cytotoxicity against HepG2 cells is assessed using standard cell viability assays, such as the MTT assay, after 72 hours of treatment. The compound is typically dissolved in DMSO.
|
| Animal Protocol |
Specific in vivo animal experimental protocols for Antimalarial agent 13 are not well-documented in the available literature. The compound has shown potent in vitro antimalarial activity. Researchers using this compound for in vivo studies would need to establish appropriate dosing and administration routes based on the specific research objectives. The compound is for research use only and not for human therapeutic use. Further studies are needed to develop and validate in vivo models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Antimalarial agent 13 are not extensively documented. The compound has a molecular weight of 261.27. It is a small molecule with a quinazoline core, which is a common scaffold in drug discovery. The compound is typically dissolved in DMSO for in vitro studies. Specific parameters such as half-life, volume of distribution, and clearance are not available. The compound is for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Antimalarial agent 13 are not extensively documented. The compound shows cytotoxicity against HepG2 cells with an EC₅₀ of 2.5 μM. This indicates that it has some level of toxicity to mammalian cells, although it is significantly less potent against HepG2 than against the parasite. The compound is for research use only and not for human therapeutic use. It should be handled with appropriate safety precautions.
|
| References | |
| Additional Infomation |
Antimalarial agent 13 is also known as Compound 1 and N2-(3-chlorophenyl)-N4-(furan-2-ylmethyl)quinazoline-2,4-diamine. It is a potent antimalarial agent with EC₅₀ values of 124 nM and 2.5 μM against P. falciparum and HepG2, respectively. It shows significant activity against P. falciparum 3D7 asexual blood-stage infections with an EC₅₀ of 134.0 nM. The compound is supplied as a solid and should be stored at -20°C. It is for research use only.
|
| Molecular Formula |
C19H15N4OCL
|
|---|---|
| Molecular Weight |
350.802
|
| Exact Mass |
350.093
|
| CAS # |
431884-01-4
|
| PubChem CID |
1285085
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
25
|
| Complexity |
426
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C(=NC(=N2)NC3=CC(=CC=C3)Cl)NCC4=CC=CO4
|
| InChi Key |
KLRNKMZSARWWTH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15ClN4O/c20-13-5-3-6-14(11-13)22-19-23-17-9-2-1-8-16(17)18(24-19)21-12-15-7-4-10-25-15/h1-11H,12H2,(H2,21,22,23,24)
|
| Chemical Name |
2-N-(3-chlorophenyl)-4-N-(furan-2-ylmethyl)quinazoline-2,4-diamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8506 mL | 14.2531 mL | 28.5063 mL | |
| 5 mM | 0.5701 mL | 2.8506 mL | 5.7013 mL | |
| 10 mM | 0.2851 mL | 1.4253 mL | 2.8506 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
